Press release
Neurofibromatoses Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Neurofibromatoses Treatment Landscape. Click here to read more @ Neurofibromatoses Pipeline Outlook [https://www.delveinsight.com/sample-request/neurofibromatoses-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Neurofibromatoses Pipeline Report
* In June 2025, Healx Limited announced a phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with progressive and/or symptomatic PN.
* In June 2025, Novartis Pharmaceuticals conducted a study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
* DelveInsight's Neurofibromatoses pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Neurofibromatoses treatment.
* The leading Neurofibromatoses Companies such as Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others.
* Promising Neurofibromatoses Pipeline Therapies such as trametinib, dabrafenib, bevacizumab, everolimus, Siltuximab , and others.
Discover groundbreaking developments in Neurofibromatoses Therapies! Gain in-depth knowledge of key Neurofibromatoses emerging drugs, and market opportunities @ Neurofibromatoses Clinical Trials Assessment [https://www.delveinsight.com/sample-request/neurofibromatoses-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Neurofibromatoses Emerging Drugs Profile
* FCN-159: Shanghai Fosun Pharmaceutical
FCN-159 is a novel, proprietary and highly potent inhibitor of mitogen-activated protein kinase kinase enzymes (MEK). It is being developed by Fochon as a monotherapy and in combination to treat solid tumors. MEK is a key member in the RAS/RAF/MEK/ERK pathway, which regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis. Dysregulation of this pathway frequently occurs in many types of cancer, in particular through mutations in BRAF, KRAS and NRAS. Currently, the drug is in Phase III stage of its development for the treatment of Neurofibromatoses.
* HLX-1502: Healx Limited
HLX-1502 is an investigational, orally administered small molecule drug developed by Healx for treating Neurofibromatosis Type 1 (NF1), a rare genetic disorder marked by tumor growth along nerves. HLX-1502 was discovered using Healx's proprietary AI platform, which accelerates the identification of potential drug candidates. The therapy has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration, underscoring its potential significance for the NF1 community. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Neurofibromatosis Type 1.
* PAS-004: Pasithea Therapeutics Corp.
PAS-004 is a small molecule allosteric inhibitor of MEK 1/2, which are dual-specificity protein kinases, in the MAPK signaling pathway. The MAPK pathway has been implicated in a variety of diseases, as it functions to drive cell proliferation, differentiation, survival and a variety of other cellular functions that, when abnormally activated, are critical for the formation and progression of tumors, fibrosis and other diseases. MEK inhibitors block phosphorylation (activation) of extracellular signal-regulated kinases (ERK). Currently, the drug is in the Phase I stage of its development for the treatment of Neurofibromatosis Type 1.
The Neurofibromatoses Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Neurofibromatoses with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neurofibromatoses Treatment.
* Neurofibromatoses Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Neurofibromatoses Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neurofibromatoses market
Stay informed about the Neurofibromatoses pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Neurofibromatoses Unmet Needs [https://www.delveinsight.com/sample-request/neurofibromatoses-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Neurofibromatoses Companies
Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others.
Neurofibromatoses Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Neurofibromatoses Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Transform your understanding of the Neurofibromatoses Pipeline! See the latest progress in drug development and clinical research @ Neurofibromatoses Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/neurofibromatoses-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Neurofibromatoses Pipeline Report
* Coverage- Global
* Neurofibromatoses Companies- Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others.
* Neurofibromatoses Pipeline Therapies- Trametinib, dabrafenib, bevacizumab, everolimus, Siltuximab , and others.
* Neurofibromatoses Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Neurofibromatoses Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Research-Access the Full Neurofibromatoses Pipeline Analysis Today! @ Neurofibromatoses Drugs and Companies [https://www.delveinsight.com/sample-request/neurofibromatoses-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Neurofibromatoses: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Neurofibromatoses- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* FCN-159: Shanghai Fosun Pharmaceutical
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* HLX-1502: Healx Limited
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* PAS-004: Pasithea Therapeutics Corp.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Neurofibromatoses Key Companies
* Neurofibromatoses Key Products
* Neurofibromatoses- Unmet Needs
* Neurofibromatoses- Market Drivers and Barriers
* Neurofibromatoses- Future Perspectives and Conclusion
* Neurofibromatoses Analyst Views
* Neurofibromatoses Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neurofibromatoses-pipeline-appears-robust-with-10-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/neurofibromatoses-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurofibromatoses Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4088539 • Views: …
More Releases from ABNewswire
Klaviyo's K:BOS Returns to Boston Sept. 25-26: Bread Loaf's Mark Milutin to Atte …
Hynes Convention Center to welcome leading DTC brands, with featured speakers from Liquid Death, Princess Polly, Daphne, AWAY, and Klaviyo.
NEWPORT BEACH, CA - September 22, 2025 - Bread Loaf, a top Klaviyo agency partner and the team behind Retention Labs, announces its participation in Klaviyo's K:BOS, the company's flagship conference taking place September 25-26, 2025 at the Hynes Convention Center in Boston, MA. The two-day event will convene consumer brands,…
The Trend Of San Diego Used Cars In The Automotive Market
The automotive market in San Diego, CA, has been experiencing a significant shift in consumer preferences. Many drivers turned attention toward pre-owned vehicles. In fact, the trend of used cars in san diego [https://www.miramarcarcenter.com/] has seen notable development in recent years, reflecting affordability and practicality. Therefore, it becomes more appealing to a wide range of buyers.
Image: https://www.abnewswire.com/upload/2025/09/54eaba0307df52b9b875862d6ec6f112.jpg
The driving trend in San Diego
San Diego's unique lifestyle and culture play a big…
Legacy Cars Guide on Financing Used Cars with Confidence
El Cajon, CA - September 22, 2025 - Buying a used car can be exciting and challenging to first-time buyers, particularly in terms of financing. Learning the fundamentals of car finance is necessary to enjoy an easy and affordable process of buying one. Legacy Cars can offer a helpful manual as it will help buyers find their way in financing solutions and make wise decisions.
Key steps legacy Cars recommends to…
Driveline Auto Explains How to Buy Used Cars with Confidence
Los Angeles, CA - Sep 22, 2025 - The car's history is one of the most important steps in the decision making process when purchasing a used car. A vehicle history report includes very useful information about the history of the car including accidents, title problems, or former owners. Driveline Auto publishes a realistic guide to guide the buyer in the used car market.
Image: https://www.abnewswire.com/upload/2025/09/1133ae8aff18a0773bbbe98ce1f31319.jpg
Guide to help buyers understand the…
More Releases for Neurofibromatoses
From $46.03B in 2024 to $99.23B by 2032: Minimally Invasive Non-Invasive Product …
Market Trend
The Minimally Invasive Non-Invasive Product Service Market is experiencing robust growth driven by technological advancements in medical devices and increasing patient demand for less invasive procedures. There is a notable trend towards integrating digital health solutions, including telemedicine and remote monitoring, to complement minimally invasive techniques, enhancing patient convenience and outcomes. Additionally, the rise of robotic-assisted surgeries and innovative imaging technologies is expanding the scope of non-invasive procedures across…
Neurofibromatosis Therapeutics Pipeline - Key Players Analysis Novartis, AstraZe …
The study analyzed that the Neurofibromatosis therapeutics pipeline comprises of approximately 25 therapeutic candidates in different stages of development.
Browse report sample at: https://www.psmarketresearch.com/market-analysis/neurofibromatoses-therapeutics-pipeline-analysis/report-sample
*Positive clinical trial results propelling the growth of the pipeline therapeutics of the Neurofibromatosis
The drugs being developed by the different pharmaceutical companies demonstrated positive clinical trial results which in-turn increasing their further development. For instance, In June 2014, Array BioPharma Inc. announced positive results of Phase I/II, combination…
Neurofibromatosis Therapeutics Pipeline Analysis Report 2018: Clinical Trials & …
The study analyzed that the Neurofibromatosis therapeutics pipeline comprises of approximately 25 therapeutic candidates in different stages of development.
Request to get the Sample Report@ https://www.psmarketresearch.com/market-analysis/neurofibromatoses-therapeutics-pipeline-analysis/report-sample
Majority of the pipeline drug candidates are being developed to be administered by oral route. Celldex Therapeutics Inc. and Merck Co. Inc. are in the process of developing a monoclonal antibody drug candidate, CDX0158, and Pembrolizumab respectively for the treatment of NF. Lixte Biotechnology…
Neurofibromatoses Type I (Von Recklinghausens Disease) - Pipeline Review and Mar …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Neurofibromatoses Type I (Von Recklinghausens Disease) - Pipeline Review, H1 2017” to its report offerings. The report provides an overview of the Neurofibromatoses Type I (Von Recklinghausens Disease) (Genetic Disorders) pipeline landscape.
Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196646
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type I (Von Recklinghausens Disease) - Pipeline Review, H1 2017,…
Neurofibromatoses Type II Market Analysis- opportunities sales, revenue, Gross M …
ReportBazzar has released its latest research-based report entitled ‘Neurofibromatoses Type II’ market.
This report provides a holistic approach to the market growth with a detailed and precise analysis of the overall competitive scenario of the Neurofibromatoses Type II market. The report also provides a detailed analysis of key trends and latest technologies, playing a prominent role in the Neurofibromatoses Type II market growth. It takes into account aspects such as drivers,…
2016 Neurofibromatoses Type I (Von Recklinghausen’s Disease) H2 Market Pipelin …
Neurofibromatoses Type I – Pipeline Review, H2 2016, provides an overview of the Neurofibromatoses Type I (Genetic Disorders) pipeline landscape.
Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and…
